-
Je něco špatně v tomto záznamu ?
Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo
Ceckova M, Libra A, Pavek P, Nachtigal P, Brabec M, Fuchs R, Staud F
Jazyk angličtina Země Austrálie
NLK
Medline Complete (EBSCOhost)
od 1998-01-01 do Před 1 rokem
Wiley Online Library (archiv)
od 1997-01-01 do 2012-12-31
- MeSH
- ABC transportéry antagonisté a inhibitory genetika metabolismus MeSH
- akridiny farmakologie MeSH
- biologický transport účinky léků MeSH
- buněčná membrána metabolismus MeSH
- buněčné linie MeSH
- choriokarcinom genetika metabolismus patologie MeSH
- financování organizované MeSH
- fluorescenční mikroskopie MeSH
- imunohistochemie MeSH
- indoly farmakologie chemie MeSH
- lidé MeSH
- messenger RNA genetika metabolismus MeSH
- mitoxantron farmakokinetika MeSH
- nádorové buněčné linie MeSH
- nádorové proteiny antagonisté a inhibitory genetika metabolismus MeSH
- P-glykoprotein genetika metabolismus MeSH
- placenta metabolismus MeSH
- polymerázová řetězová reakce s reverzní transkripcí MeSH
- regulace genové exprese u nádorů MeSH
- těhotenství MeSH
- tetrahydroisochinoliny farmakologie MeSH
- western blotting MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- zvířata MeSH
1. Breast cancer resistance protein (BCRP, ABCG2) is a drug efflux transporter that is believed to affect the drug disposition of several drugs and xenobiotics. In the present study, we evaluated the localization and functional expression of BCRP in the human choriocarcinoma cell line BeWo, an in vitro model of the human trophoblast, and compared it with the expression of P-glycoprotein (MDR1, ABCB1) as the most widely studied placental transporter. In addition, the expression of BCRP at the mRNA level was compared with that of MDR1 in the human term placenta. 2. Western blotting analysis revealed high endogenous expression of BCRP protein in BeWo cells. Using indirect immunofluorescence microscopy, we found that the BCRP transporter appears to be localized predominantly at the apical plasma membrane. Functional studies showed a significant effect of the BCRP inhibitors GF120918 (5 micromol/L) and Ko143 (1 micromol/L) on mitoxantrone accumulation and, thus, confirmed efflux activity of BCRP in BeWo cells. 3. Using absolute mRNA quantification with real-time reverse transcription-polymerase chain reaction, we found high expression of BCRP in BeWo cells, whereas no transcript of MDR1 (P-glycoprotein), the most extensively studied drug transporter, was detected. 4. In the human placenta, BCRP was localized predominantly in the syncytiotrophoblast layer; however, immunopositivity for the BXP-21 antibody was also observed in fetal vessels of the chorionic villi. The number of BCRP transcripts in the human term placenta was found to be more than 10-fold higher compared with the expression of MDR1. 5. In conclusion, we suggest that BeWo cells could serve as a suitable in vitro model to study trans-trophoblast transport of BCRP substrates and that placental BCRP can play an important role in preventing the accumulation of potentially toxic xenobiotics in the trophoblast cells.
- 000
- 00000naa 2200000 a 4500
- 001
- bmc07520309
- 003
- CZ-PrNML
- 005
- 20111210131055.0
- 008
- 090331s2006 at e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a at
- 100 1_
- $a Čečková, Martina $7 xx0049092
- 245 10
- $a Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo / $c Ceckova M, Libra A, Pavek P, Nachtigal P, Brabec M, Fuchs R, Staud F
- 314 __
- $a Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Heyrovskeho 1203, CZ-50005 Hradec Kralove, Czech Republic
- 520 9_
- $a 1. Breast cancer resistance protein (BCRP, ABCG2) is a drug efflux transporter that is believed to affect the drug disposition of several drugs and xenobiotics. In the present study, we evaluated the localization and functional expression of BCRP in the human choriocarcinoma cell line BeWo, an in vitro model of the human trophoblast, and compared it with the expression of P-glycoprotein (MDR1, ABCB1) as the most widely studied placental transporter. In addition, the expression of BCRP at the mRNA level was compared with that of MDR1 in the human term placenta. 2. Western blotting analysis revealed high endogenous expression of BCRP protein in BeWo cells. Using indirect immunofluorescence microscopy, we found that the BCRP transporter appears to be localized predominantly at the apical plasma membrane. Functional studies showed a significant effect of the BCRP inhibitors GF120918 (5 micromol/L) and Ko143 (1 micromol/L) on mitoxantrone accumulation and, thus, confirmed efflux activity of BCRP in BeWo cells. 3. Using absolute mRNA quantification with real-time reverse transcription-polymerase chain reaction, we found high expression of BCRP in BeWo cells, whereas no transcript of MDR1 (P-glycoprotein), the most extensively studied drug transporter, was detected. 4. In the human placenta, BCRP was localized predominantly in the syncytiotrophoblast layer; however, immunopositivity for the BXP-21 antibody was also observed in fetal vessels of the chorionic villi. The number of BCRP transcripts in the human term placenta was found to be more than 10-fold higher compared with the expression of MDR1. 5. In conclusion, we suggest that BeWo cells could serve as a suitable in vitro model to study trans-trophoblast transport of BCRP substrates and that placental BCRP can play an important role in preventing the accumulation of potentially toxic xenobiotics in the trophoblast cells.
- 650 _2
- $a ABC transportéry $x antagonisté a inhibitory $x genetika $x metabolismus $7 D018528
- 650 _2
- $a akridiny $x farmakologie $7 D000166
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a biologický transport $x účinky léků $7 D001692
- 650 _2
- $a western blotting $7 D015153
- 650 _2
- $a buněčné linie $7 D002460
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a buněčná membrána $x metabolismus $7 D002462
- 650 _2
- $a choriokarcinom $x genetika $x metabolismus $x patologie $7 D002822
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a regulace genové exprese u nádorů $7 D015972
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunohistochemie $7 D007150
- 650 _2
- $a indoly $x farmakologie $x chemie $7 D007211
- 650 _2
- $a fluorescenční mikroskopie $7 D008856
- 650 _2
- $a mitoxantron $x farmakokinetika $7 D008942
- 650 _2
- $a nádorové proteiny $x antagonisté a inhibitory $x genetika $x metabolismus $7 D009363
- 650 _2
- $a P-glykoprotein $x genetika $x metabolismus $7 D020168
- 650 _2
- $a placenta $x metabolismus $7 D010920
- 650 _2
- $a těhotenství $7 D011247
- 650 _2
- $a messenger RNA $x genetika $x metabolismus $7 D012333
- 650 _2
- $a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
- 650 _2
- $a tetrahydroisochinoliny $x farmakologie $7 D044005
- 650 _2
- $a financování organizované $7 D005381
- 700 1_
- $a Libra, Antonín. $7 _BN007788
- 700 1_
- $a Pávek, Petr $7 xx0093070
- 700 1_
- $a Nachtigal, Petr $7 uk2009304471
- 700 1_
- $a Brabec, Marianne
- 700 1_
- $a Fuchs, Renate
- 700 1_
- $a Štaud, František, $d 1970- $7 stk2007393932
- 773 0_
- $w MED00007158 $t Clinical and experimental pharmacology & physiology $g Roč. 33, č. 1-2 (2006), s. 58-65 $x 0305-1870
- 910 __
- $a ABA008 $b x $y 9
- 990 __
- $a 20090312170439 $b ABA008
- 991 __
- $a 20090717082604 $b ABA008
- 999 __
- $a ok $b bmc $g 638112 $s 490910
- BAS __
- $a 3
- BMC __
- $a 2006 $b 33 $c 1-2 $d 58-65 $i 0305-1870 $m Clinical and experimental pharmacology & physiology $x MED00007158
- LZP __
- $a 2009-B1/vtme